Emile Loria
Chairman chez Portable Genomics, Inc.
Fortune : 14 M $ au 31/03/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Gérard Tobelem | M | 76 |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | 10 ans |
Anne-Laure Autret-Cornet | F | - | 8 ans | |
Maryvonne Hiance | F | 75 | 8 ans | |
Nicolas Poirier | M | 42 | 8 ans | |
Stéphane Silvente | M | - |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | 6 ans |
Philippe Lefèbvre | M | - |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | 6 ans |
Didier Hoch | M | 68 | 8 ans | |
Brigitte Dreno | M | 71 | 7 ans | |
Magda Marquet | M | 65 |
Portable Genomics, Inc.
| - |
Jean-Michel Foidart | M | 75 |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | - |
Patrick Stragier | M | - |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | - |
Caroline Thielen | M | - |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | - |
Christophe Fremont | M | - |
Portable Genomics, Inc.
| - |
Eric Vigouroux | M | - |
Portable Genomics, Inc.
| - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Alexis Peyroles | M | - | 6 ans | |
Robert J. de Vaere | M | 66 |
Epimmune, Inc.
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 6 ans |
Sophie Brouard | M | 53 | - | |
Bernard Vanhove | M | - | 2 ans | |
Walter Flamenbaum | M | 81 | 6 ans | |
Jean-Patrick Demonsang | M | 71 | 9 ans | |
Sylvie Grégoire | M | 63 |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 2 ans |
Michael Grey | M | 71 |
Epimmune, Inc.
| - |
David de Weese | M | 82 | 3 ans | |
Georges Hibon | M | 86 |
Epimmune, Inc.
| - |
Gerard A. Tardy | M | - | - | |
Jean Théron | M | - | 5 ans | |
Robert Beck | M | 70 |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 4 ans |
Diane Jorkasky | M | 72 | - | |
James G. Bender | M | 74 |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 6 ans |
Guy Chatelain | M | - | 6 ans | |
Jean Deleage | M | 83 |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 4 ans |
William T. Comer | M | 85 |
Epimmune, Inc.
| 11 ans |
Ted Greene | M | 81 |
Epimmune, Inc.
| - |
Statistiques
Pays | Relations | % du total |
---|---|---|
France | 16 | 48,48% |
Etats-Unis | 12 | 36,36% |
Belgique | 6 | 18,18% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Emile Loria
- Réseau Personnel